Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2742844 | 0.89 | CA12 (0.45) | ITGB3ITGA2BMAOBCA12CA1 | |
| SCHEMBL231156 | 0.89 | CA12 (0.45) | ITGB3ITGA2BMAOBCA12CA1 | |
| SCHEMBL18025354 | 0.88 | CA12 (0.44) | ITGB3ITGA2BMAOBCA12CA1 | |
| SCHEMBL16441206 | 0.85 | CA12 (0.44) | ITGB3ITGA2BMAOBCA12CA1 | |
| SCHEMBL17166629 | 0.85 | CA12 (0.44) | ITGB3ITGA2BMAOBCA12CA1 | |
| SCHEMBL20215813 | 0.84 | LTA4H (0.47) | ITGB3ITGA2BCA12CA1CA2 | |
| SCHEMBL10001634 | 0.84 | LTA4H (0.47) | ITGB3ITGA2BCA12CA1CA2 | |
| SCHEMBL10001633 | 0.83 | CA12 (0.47) | ITGB3ITGA2BMAOBCA12CA1 | |
| Hydrochloric Acid SCHEMBL5755082 | 0.83 | LTA4H (0.46) | ITGB3ITGA2BCA12CA1CA2 | |
| SCHEMBL25794373 | 0.82 | ITGB3 (0.72) | ITGB3ITGA2BCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052471-B1 | METHODS FOR POST-FABRICATION FUNCTIONALIZATION OF POLY(ESTER UREAS) | UNIV AKRON (US) | 2023-06-21 | — | — | EP | disclosed |
| US-9988492-B2 | Methods for post-fabrication functionalization of poly(ester ureas) | THE UNIVERSITY OF AKRON (US) | 2018-06-05 | — | — | US | disclosed |
| US-20160237212-A1 | METHODS FOR POST-FABRICATION FUNCTIONALIZATION OF POLY(ESTER UREAS) | THE UNIVERSITY OF AKRON (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160237212-A1 | METHODS FOR POST-FABRICATION FUNCTIONALIZATION OF POLY(ESTER UREAS) | THE UNIVERSITY OF AKRON (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2015048728-A1 | METHODS FOR POST-FABRICATION FUNCTIONALIZATION OF POLY(ESTER UREAS) | THE UNIVERSITY OF AKRON (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237212-A1 | METHODS FOR POST-FABRICATION FUNCTIONALIZATION OF POLY(ESTER UREAS) | PTMS, MUSK, DSTYK | ITGB3 1928/4885ITGA2B 3864/4885MAOB 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.